<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>journal-jmsr</PublisherName>
<JournalTitle>Journal of Medical and Surgical Research</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Special Issue "Pathology"</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>March, 2023</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>JMSR Pathology</ArticleType>
<ArticleTitle>The histoprognostic value of tertiary lymphoid structures in endometrial cancer.</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>0</FirstPage>
<LastPage>0</LastPage>
<AuthorList>
<Author>
<FirstName>S.Aitbrahim</FirstName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>L.Tahiri</FirstName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>S.Moqran</FirstName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName> </FirstName>
<LastName>Ch.Bouchikhi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>H.El</FirstName>
<LastName>Fatemi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Introduction: In postmenopausal women, endometrial adenocarcinoma is the most prevalent malignant uterine tumor. Endometrial adenocarcinomas are currently classified into four subtypes, listed from best to worst prognosis: ultramutant POLE, hypermutant with microsatellite instability, low copy number, and high copy number. This classification has recently been incorporated into the ESGO guidelines to stratify prognostic groups and guide further treatment. Tertiary lymphoid structures, also known as ectopic lymphoid structures, have emerged as a new prognostic factor.
Materiel et methods: A retrospective descriptive study was conducted over a one-year period, from January , 2022 to December, 2022, on 27 cases of endometrial cancer that had been histologically confirmed and were being treated at the Hassan II University Hospital in Fez. We reviewed the 27 cases to determine the presence of secondary lymphoid structures, and we will go over the key clinical and histoprognostic data in relation to secondary lymphoid structures.
Results: There were 26 women with endometrial cancer, with an average age of 56.9 years and ages ranging from 37 to 76.
Endometrial tumors were classified into four histological subtypes: 57.69% of endometrioid adenocarcinomas, 11.53% of serous adenocarcinomas and 11.53% of poorly differentiated carcinomas According to the FIGO classification, nearly 73.03% of endometrial cancer cases were diagnosed at an early stage [I,II], while 26.92% were diagnosed at a late stage [III, IV].
In 30.76% , we found tertiary lymphoid structures at the tumor invasion front and in the myometrium.Vascular emboli were found in 65.38% of the cases .
These results could be used to establish correlations between tertiary lymphoid structures, vascular emboli, TILS, histological type . The histological subtype most frequently connected to tertiary lymphoid tissues was endometroid adenocarcinoma grade II (26.66%). Tertiary lymphoid structures were detected in early stages (I, II) in 40%, vascular emboli (EV3) in 62.5%, and the presence of TILS in 83.33% of cases.
Discussion: Tertiary lymphoid structures (TLS) are ectopic lymphoid structures that form in and around cancers. They are lymphoid cell aggregates organized in the form of follicles, with a zone of T cells and a zone of B cells. TLSs have been found in a variety of solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer, and hepatocellular carcinoma.
Conclusion: The prognostic value of tertiary lymphoid structures has only been partially explained. Extensive analyses will be required to comprehend and characterize these structures .</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Endometrial adenocarcinoma , Tertiary lymphoid structures , Prognostic Groups ,B CELLS</Keywords>
<URLs>
<Abstract>https://journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=14390&title=The histoprognostic value of tertiary lymphoid structures in endometrial cancer.</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Zhao, Zhan, Ding, Hui, Lin, Zheng-bin, et al. Relationship between tertiary lymphoid structure and the prognosis and clinicopathologic characteristics in solid tumors. International Journal of Medical Sciences, 2021, vol. 18, no 11, p. 2327.
Goc, Jand;eacute;rand;eacute;my, Fridman, Wolf-Herman, Sautand;egrave;s-Fridman, Catherine, et al. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology, 2013, vol. 2, no 12, p. e26836.
Horeweg, Nanda, Workel, Hagma H., Loiero, Dominik, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, vol. 13, no 1, p. 1373.
QIN, Meng, HAMANISHI, Junzo, UKITA, Masayo, et al. Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer. Cancer Immunology, Immunotherapy, 202, p. 1-12.
Sautand;egrave;s-Fridman, Catherine, Petitprez, Florent, Calderaro, Julien, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews Cancer, 2019, vol. 19, no 6, p. 307-325.</References>
</References>
</Journal>
</Article>
</ArticleSet>